Receptor‑interacting serine/threonine‑protein kinase 1 promotes the progress and lymph metastasis of gallbladder cancer

Zhu,Guangwei; Du,Qiang; Chen,Xiao; Wang,Xiaoqian; Tang,Nanhong; She,Feifei; Chen,Yanling

doi:10.3892/or.2019.7331

Receptor‑interacting serine/threonine‑protein kinase 1 promotes the progress and lymph metastasis of gallbladder cancer

Authors:
- Guangwei Zhu
- Qiang Du
- Xiao Chen
- Xiaoqian Wang
- Nanhong Tang
- Feifei She
- Yanling Chen
View Affiliations

Affiliations: Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Union Hospital, Fujian Medical University, Fuzhou, Fujian 350001, P.R. China, Key Laboratory of Ministry of Education for Gastrointestinal Cancer and Key Laboratory of Tumor Microbiology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350001, P.R. China
Published online on: September 23, 2019 https://doi.org/10.3892/or.2019.7331
Pages: 2435-2449
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Receptor‑interacting serine/threonine‑protein kinase 1 (RIP‑1) is highly expressed in gallbladder cancer, and is very important in promoting tumor proliferation and invasion. The underlying mechanism in this promotion is the RIP‑1‑nuclear factor κ‑B (NF‑κB) and activator protein 1 (AP‑1)‑vascular endothelial growth factor‑C (VEGF‑C) signaling pathways. However, the precise mechanisms by which RIP‑1 regulates VEGF‑C expression are still unknown. The current study aims to clarify the detailed mechanisms by which RIP‑1 upregulates VEGF‑C expression. In the current study, the authors constructed various VEGF‑C promoter deletions, VEGF‑C promoter mutations and RIP‑1 overexpression plasmids, and silenced RIP‑1 with a small interfering RNA. Promoter analysis, an electrophoretic mobility shift assay, a chromatin immunoprecipitation assay was then performed, and an orthotopic transplantation model in nude mice was established by modified methods previously used. The authors also found that the core region for luciferase activity in the VEGF‑C promoter was ‑332 to ‑190 nt, in which there are two overlapping AP‑1 sites and an NF‑κB site. RIP‑1 was demonstrated to activate transcription factors NF‑κB and AP‑1 to combine with the core region and enhance VEGF‑C promoter activity. In conclusion, the current study illustrated the mechanisms by which RIP‑1 regulates VEGF‑C expression, by activating NF‑κB and AP‑1 to combine with the ‑332 to ‑190 nt area of the VEGF‑C promoter. By establishing an orthotopic mouse model of gallbladder cancer tumors, it was further elucidated that RIP‑1 promotes gallbladder cancer metastasis. The findings provide evidence that targeting RIP‑1 may prove to be useful in the treatment of gallbladder cancer.

View Figures

View References

1	Bartlett DL, Fong Y, Fortner JG, Brennan MF and Blumgart LH: Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg. 224:639–646. 1996. View Article : Google Scholar : PubMed/NCBI
2	Cubertafond P, Gainant A and Cucchiaro G: Surgical treatment of 724 carcinomas of the gallbladder. Results of the French surgical association survey. Ann Surg. 219:275–280. 1994. View Article : Google Scholar : PubMed/NCBI
3	Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S and La Vecchia C: Epidemiology of biliary tract cancers: An update. Ann Oncol. 20:146–159. 2009. View Article : Google Scholar : PubMed/NCBI
4	Shukla VK, Chauhan VS, Mishra RN and Basu S: Lifestyle, reproductive factors and risk of gallbladder cancer. Singapore Med J. 49:912–915. 2008.PubMed/NCBI
5	Miller G and Jarnagin WR: Gallbladder carcinoma. Eur J Surg Oncol. 34:306–312. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zhu G, Chen X, Wang X, Li X, Du Q, Hong H, Tang N, She F and Chen Y: Expression of the RIP-1 gene and its role in growth and invasion of human gallbladder carcinoma. Cell Physiol Biochem. 34:1152–1165. 2014. View Article : Google Scholar : PubMed/NCBI
7	Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, Ramnarain DB, Xiao G, Saha D, Boothman DA, et al: The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res. 69:2809–2816. 2009. View Article : Google Scholar : PubMed/NCBI
8	Hsu H, Huang J, Shu HB, Baichwal V and Goeddel DV: TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 4:387–396. 1996. View Article : Google Scholar : PubMed/NCBI
9	Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ and Leder P: The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 8:297–303. 1998. View Article : Google Scholar : PubMed/NCBI
10	Hur GM, Lewis J, Yang Q, Lin Y, Nakano H, Nedospasov S and Liu ZG: The death domain kinase RIP has an essential role in DNA damage-induced NF-kappa B activation. Genes Dev. 17:873–882. 2003. View Article : Google Scholar : PubMed/NCBI
11	Devin A, Lin Y and Liu ZG: The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep. 4:623–627. 2003. View Article : Google Scholar : PubMed/NCBI
12	Liu ZG, Hsu H, Goeddel DV and Karin M: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell. 87:565–576. 1996. View Article : Google Scholar : PubMed/NCBI
13	Pacifico F and Leonardi A: NF-kappaB in solid tumors. Biochem Pharmacol. 72:1142–1152. 2006. View Article : Google Scholar : PubMed/NCBI
14	Zhu G, Du Q, Wang X, Tang N, She F and Chen Y: TNF-α promotes gallbladder cancer cell growth and invasion through autocrine mechanisms. Int J Mol Med. 33:1431–1440. 2014. View Article : Google Scholar : PubMed/NCBI
15	Horiuchi H, Kawamata H, Fujimori T and Kuroda Y: A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: Analysis in a novel orthotopic inoculation model. Int J Oncol. 23:957–963. 2003.PubMed/NCBI
16	Du Q, Jiang L, Wang XQ, Pan W, She FF and Chen YL: Establishment of and comparison between orthotopic xenograft and subcutaneous xenograft models of gallbladder carcinoma. Asian Pac J Cancer Prev. 15:3747–3752. 2014. View Article : Google Scholar : PubMed/NCBI
17	Homma S, Hasumura S, Nagamori S and Kameda H: Establishment and characterization of a human gall bladder carcinoma cell line NOZ. Hum Cell. 1:95–97. 1988.PubMed/NCBI
18	Heckman KL and Pease LR: Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc. 2:924–932. 2007. View Article : Google Scholar : PubMed/NCBI
19	Rettino A, Rafanelli F, Genovese G, Goracci M, Cifarelli RA, Cittadini A and Sgambato A: Identification of Sp1 and GC-boxes as transcriptional regulators of mouse Dag1 gene promoter. Am J Physiol Cell Physiol. 297:C1113–C1123. 2009. View Article : Google Scholar : PubMed/NCBI
20	Wu YL, Peng XE, Wang D, Chen WN and Lin X: Human liver fatty acid binding protein (hFABP1) gene is regulated by liver-enriched transcription factors HNF3β and C/EBPα. Biochimie. 94:384–392. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ceelie H, Spaargaren-Van Riel CC, De Jong M, Bertina RM and Vos HL: Functional characterization of transcription factor binding sites for HNF1-alpha, HNF3-beta (FOXA2), HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer. J Thromb Haemost. 1:1688–1698. 2003. View Article : Google Scholar : PubMed/NCBI
22	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
23	Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL and Dirix LY: Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation. Eur J Cancer. 32A:2474–2484. 1996. View Article : Google Scholar : PubMed/NCBI
24	Du Q, Jiang L, Wang X, Wang M, She F and Chen Y: Tumor necrosis factor-α promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-κB-mediated upregulation of vascular endothelial growth factor-C. Cancer Sci. 105:1261–1271. 2014. View Article : Google Scholar : PubMed/NCBI
25	O'Donnell MA and Ting AT: RIP1 comes back to life as a cell death regulator in TNFR1 signaling. FEBS J. 278:877–887. 2011. View Article : Google Scholar : PubMed/NCBI
26	Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ and Yuan J: Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell. 135:1311–1323. 2008. View Article : Google Scholar : PubMed/NCBI
27	Ting AT, Pimentel-Muiños FX and Seed B: RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J. 15:6189–6196. 1996. View Article : Google Scholar : PubMed/NCBI
28	Devin A, Lin Y, Yamaoka S, Li Z, Karin M and Liu Z: The alpha and beta subunits of IkappaB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF. Mol Cell Biol. 21:3986–3994. 2001. View Article : Google Scholar : PubMed/NCBI
29	Han W, Xie J, Fang Y, Wang Z and Pan H: Nec-1 enhances shikonin-induced apoptosis in leukemia cells by inhibition of RIP-1 and ERK1/2. Int J Mol Sci. 13:7212–7225. 2012. View Article : Google Scholar : PubMed/NCBI
30	Azijli K, Yuvaraj S, Peppelenbosch MP, Würdinger T, Dekker H, Joore J, van Dijk E, Quax WJ, Peters GJ, de Jong S and Kruyt FA: Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J Cell Sci. 125:4651–4661. 2012. View Article : Google Scholar : PubMed/NCBI
31	Jüttner S, Wissmann C, Jöns T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W and Höcker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: Two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 24:228–240. 2006. View Article : Google Scholar : PubMed/NCBI
32	Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T and Uchida Y: Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 97:457–464. 2003. View Article : Google Scholar : PubMed/NCBI
33	Achen MG, McColl BK and Stacker SA: Focus on lymphangiogenesis in tumor metastasis. Cancer Cell. 7:121–127. 2005. View Article : Google Scholar : PubMed/NCBI
34	Timoshenko AV, Rastogi S and Lala PK: Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer. 97:1090–1098. 2007. View Article : Google Scholar : PubMed/NCBI
35	Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL and Gill PS: Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer. 104:603–610. 2003. View Article : Google Scholar : PubMed/NCBI
36	Shimada H, Endo I, Togo S, Nakano A, Izumi T and Nakagawara G: The role of lymph node dissection in the treatment of gallbladder carcinoma. Cancer. 79:892–899. 1997. View Article : Google Scholar : PubMed/NCBI
37	Chen Y, Jiang L, She F, Tang N, Wang X, Li X, Han S and Zhu J: Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism. Mol Cell Biochem. 345:77–89. 2010. View Article : Google Scholar : PubMed/NCBI
38	Ernst P and Smale ST: Combinatorial regulation of transcription. I: General aspects of transcriptional control. Immunity. 2:311–319. 1995. View Article : Google Scholar : PubMed/NCBI
39	Fidler IJ: Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 50:6130–6138. 1990.PubMed/NCBI